The European Medicines Agency rejected Acrescent, Lundbeck's combination Alzheimer's treatment, last week, but the Scandinavian drugmaker is already moving forward with a next-generation treatment for the same ailment. Lundbeck is in the middle stages of development for AE58054, and the company is in search of partners to help develop the treatment, a spokesman told Bloomberg. Report